Department of Internal Medicine and Systemic Disease, Clinical Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy.
JACC Cardiovasc Interv. 2009 Mar;2(3):185-94. doi: 10.1016/j.jcin.2008.12.005.
This retrospective study sought to assess the clinical and angiographic long-term outcome after implanting drug-eluting stents in bifurcation lesions with the T-provisional (T-prov) technique and mini-crush (MC) technique.
The best option on the treatment of coronary bifurcation lesions is a subject of considerable debate. However, recent evidence suggests that bifurcation lesions might be treated by drug-eluting stent on both branches using the MC technique with a low rate of major adverse cardiac event and restenosis.
From April 2004 to July 2006, 457 patients were consecutively treated with either MC technique (n = 199) or T-prov technique (n = 258). Of these latter, 170 patients were treated with 1 stent and 88 patients with 2 stents. The 9-month angiographic follow-up was completed in 188 of 229 (82.1%) bifurcation lesions of MC patients and in 207 of 266 lesions (77.8%) of T-prov patients.
After a propensity score adjustment, 2-year cumulative major adverse cardiac events were similar between groups (p = 0.16). The MC group compared with the T-prov 1-stent group had significantly lower main and side branches restenosis (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.27 to 0.99; p = 0.047; and HR: 0.41, 95% CI: 0.20 to 0.85; p = 0.016, respectively). However, the MC group compared with the T-prov-only group had significantly lower side branch restenosis (HR: 0.55, 95% CI: 0.37 to 0.82; p = 0.004).
Both techniques of bifurcation treatment met high procedural success with low complication rates and similar major adverse cardiac event long-term outcome. However, the MC technique yields a lower restenosis rate at both main and side branches. These results may confirm the advantage of using prescheduled 2-stent technique to give a complete coverage of the side branches' ostium.
本回顾性研究旨在评估经皮冠状动脉介入治疗(PCI)分叉病变中应用 T 型(T-prov)技术和迷你(MC)技术的药物洗脱支架植入术的临床和血管造影长期结果。
关于冠状动脉分叉病变的最佳治疗方法一直存在较大争议。然而,最近的证据表明,使用 MC 技术对两支分叉病变的分支进行药物洗脱支架治疗,其主要不良心脏事件和再狭窄的发生率较低。
从 2004 年 4 月至 2006 年 7 月,457 例患者连续接受 MC 技术(n=199)或 T-prov 技术(n=258)治疗。其中 170 例患者植入 1 枚支架,88 例患者植入 2 枚支架。MC 组的 188 例(82.1%)和 T-prov 组的 207 例(77.8%)患者完成了 9 个月的血管造影随访。
在倾向评分调整后,两组 2 年累积主要不良心脏事件发生率相似(p=0.16)。与 T-prov 单支架组相比,MC 组主支和分支的再狭窄率显著降低(风险比[HR]:0.52,95%置信区间[CI]:0.27 至 0.99;p=0.047;和 HR:0.41,95%CI:0.20 至 0.85;p=0.016)。然而,与 T-prov 组相比,MC 组的分支再狭窄率显著降低(HR:0.55,95%CI:0.37 至 0.82;p=0.004)。
两种分叉病变处理技术均具有较高的手术成功率,并发症发生率低,长期主要不良心脏事件结局相似。然而,MC 技术可降低主支和分支的再狭窄率。这些结果可能证实了使用预定的双支架技术完全覆盖分支开口的优势。